Inogen, Inc.

As of September 8, 2025, Inogen, Inc. shows a mildly bullish technical trend supported by positive MACD and Bollinger Bands, despite some bearish signals in daily moving averages and negative longer-term returns relative to the S&P 500.

As of February 24, 2022, Inogen, Inc. is considered overvalued with a risky valuation grade due to negative financial metrics, including a P/E ratio and poor returns, significantly underperforming its peers and the S&P 500.

As of February 24, 2022, Inogen, Inc. is considered overvalued and risky due to negative earnings, poor financial ratios, and significant operational inefficiencies, with a year-to-date return of -27.26%, underperforming the S&P 500.

As of June 17, 2025, Inogen, Inc. shows a mildly bearish trend due to daily moving averages, despite some bullish signals from the weekly MACD and monthly KST, indicating a cautious approach is advisable.

As of March 2022, Inogen, Inc.'s management team includes Dr. Heath Lukatch (Independent Chairman), Mr. Scott Wilkinson (President and CEO), and several independent directors: Mr. Benjamin Anderson-Ray, Mr. Scott Beardsley, Mr. R. Scott Greer, Mr. Raymond Huggenberger, and Mr. Loren McFarland. This diverse team guides the company's governance and strategic direction.

Inogen, Inc. is a medical technology company that develops and markets portable oxygen concentrators for patients with chronic respiratory conditions. As of March 2025, it reported net sales of $82 million and a net loss of $6 million, with a market cap of $174.23 million.

As of Jun 18, Inogen, Inc. has a market capitalization of 174.23 million and reported net sales of 339.96 million with a net profit of -27.48 million over the latest four quarters. Shareholder's funds are at 173.86 million, and total assets amount to 296.19 million.